Frovatriptan
Frovatriptan
CLINICAL USE
Acute relief of migraine
DOSE IN NORMAL RENAL FUNCTION
2.5 mg; a second dose can be taken if required after at least 2 hoursMaximum daily dose is 5 mg
PHARMACOKINETICS
Molecular weight                           :243.3 %Protein binding                           :15 %Excreted unchanged in urine     : 10–32 Volume of distribution (L/kg)       :3–4.2half-life – normal/ESRD (hrs)      :26/ Unchanged DOSE IN RENAL IMPAIRMENT
GFR (mL/MIN)
20 to 50     : Dose as in normal renal function 10 to 20     : Dose as in normal renal function <10           : Dose as in normal renal function DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                :Likely dialysability. Dose as in normal renal function HD                     :Likely dialysability. Dose as in normal renal functionHDF/high flux   :Likely dialysability. Dose as in normal renal functionCAV/VVHD      :Likely dialysability. Dose as in normal renal function IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugsAntidepressants: blood levels of frovatriptan increased 27–49% by fluvoxamine – avoid concomitant use; possibly increased serotonergic effects with duloxetine and SSRIs; increased serotonergic effects with St John’s wort – avoid concomitant use Ergot alkaloids: increased risk of vasospasm ADMINISTRATION
Reconstition
– Route
Oral Rate of Administration
–Comments
See how to identify renal failure stages according to GFR calculation
See how to diagnose irreversible renal disease
Home